Drug intelligence / Profile preview

MK-633

Development stage: Phase 2
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

MK-633 is an oral agent that was under development by Merck for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The drug was investigated as a potential therapy to address respiratory symptoms and disease progression in COPD, but there is no evidence it reached advanced clinical development or approval. Its precise mechanism of action has not been publicly disclosed.

Other names: setileuton

Targets

P2X3 (P2X purinoceptor 3)P2XR (P2X receptor family)

Beyond the preview

Go deeper on MK-633.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-633.

Explore the full profile